

AMENDMENTS

In the claims:

Please amend the claims as follows.

Please cancel claims 70-72.

Claims 1-74 (Canceled).

75. (Previously Presented) An isolated anti-TPBD antibody having specific reactivity with a TPBD amino acid sequence selected from the group consisting of SEQ ID NOS: 12, 24 and 25.

Claim 76 (Canceled).

77. (Previously Presented) The isolated anti-TPBD antibody of claim 75, wherein said antibody has specific reactivity with SEQ ID NO:12.

Claim 78 (Canceled).

79. (Previously Presented) The isolated anti-TPBD antibody of claim 75, wherein said antibody has specific reactivity with SEQ ID NO:24.

80. (Previously Presented) The isolated anti-TPBD antibody of claim 75, wherein said antibody has specific reactivity with SEQ ID NO:25.

81. (Previously Presented) An antibody according to claim 75, wherein said antibody is a monoclonal antibody.

82. (Previously Presented) A cell line producing the monoclonal antibody of claim 81.

83. (Previously Presented) An antibody according to claim 75, wherein said antibody is a polyclonal antibody.

Claims 84-86 (Canceled).

87. (Previously Presented) An antibody according to claim 77, wherein said antibody is a monoclonal antibody.

88. (Previously Presented) A cell line producing the monoclonal antibody of claim 87.

89. (Previously Presented) An antibody according to claim 77, wherein said antibody is a polyclonal antibody.

Claims 91-93 (Canceled).

93. (Previously Presented) An antibody according to claim 79, wherein said antibody is a monoclonal antibody.

94. (Previously Presented) A cell line producing the monoclonal antibody of claim 93.

95. (Previously Presented) An antibody according to claim 79, wherein said antibody is a polyclonal antibody.

96. (Previously Presented) An antibody according to claim 80, wherein said antibody is a monoclonal antibody.

97. (Previously Presented) A cell line producing the monoclonal antibody of claim 96.

98. (Previously Presented) An antibody according to claim 80, wherein said antibody is a polyclonal antibody.

Please add the following new claims.

99. (New) The cell line of claim 82, wherein said cell line is a hybridoma.

100. (New) The cell line of claim 88, wherein said cell line is a hybridoma.

101. (New) The cell line of claim 94, wherein said cell line is a hybridoma.

102. (New) The cell line of claim 97, wherein said cell line is a hybridoma.

103. (New) An isolated anti-TPBD antibody having specific reactivity with a TPBD amino acid sequence selected from the group consisting of SEQ ID NOS: 12, 24 and 25, wherein said antibody inhibits the association of said TPBD with a TNF family receptor, TRAF protein or a TRAF-associated protein.

104. (New) The isolated anti-TPBD antibody of claim 103, wherein said TNF family receptor is TNF-R2, said TRAF protein is human TRAF6 and said TRAF-associated protein is I-TRAF.

105. (New) The isolated anti-TPBD antibody of claim 103, wherein said TNF family receptor is CD40, said TRAF protein is human TRAF2 and said TRAF-associated protein is I-TRAF.

106. (New) The isolated anti-TPBD antibody of claim 103, wherein said antibody has specific reactivity with SEQ ID NO:12.

107. (New) The isolated anti-TPBD antibody of claim 103, wherein said antibody has specific reactivity with SEQ ID NO:24.

108. (New) The isolated anti-TPBD antibody of claim 103, wherein said antibody has specific reactivity with SEQ ID NO:25.

109. (New) An antibody according to claim 103, wherein said antibody is a monoclonal antibody.

110. (New) A cell line producing the monoclonal antibody of claim 109.

111. (New) The cell line of claim 110, wherein said cell line is a hybridoma.

112. (New) An antibody according to claim 103, wherein said antibody is a polyclonal antibody.

113. (New) An antibody according to claim 106, wherein said antibody is a monoclonal antibody.

114. (New) A cell line producing the monoclonal antibody of claim 113.

115. (New) The cell line of claim 114, wherein said cell line is a hybridoma.
116. (New) An antibody according to claim 106, wherein said antibody is a polyclonal antibody.
117. (New) An antibody according to claim 107, wherein said antibody is a monoclonal antibody.
118. (New) A cell line producing the monoclonal antibody of claim 117.
119. (New) The cell line of claim 118, wherein said cell line is a hybridoma.
120. (New) An antibody according to claim 107, wherein said antibody is a polyclonal antibody.
121. (New) An antibody according to claim 108, wherein said antibody is a monoclonal antibody.
122. (New) A cell line producing the monoclonal antibody of claim 121.
123. (New) The cell line of claim 122, wherein said cell line is a hybridoma.
124. (New) An antibody according to claim 108, wherein said antibody is a polyclonal antibody.